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Abstract
Background: Human cell types respond differently to infection by human immunodeficiency virus
(HIV). Defining specific interactions between host cells and viral proteins is essential in
understanding how viruses exploit cellular functions and the innate strategies underlying cellular
control of HIV replication. The HIV Rev protein is a post-transcriptional inducer of HIV gene
expression and an important target for interaction with cellular proteins. Identification of Rev-
modulating cellular factors may eventually contribute to the design of novel antiviral therapies.
Results: Yeast-two hybrid screening of a T-cell cDNA library with Rev as bait led to isolation of a
novel human cDNA product (16.4.1). 16.4.1-containing fusion proteins showed predominant
cytoplasmic localization, which was dependent on CRM1-mediated export from the nucleus.
Nuclear export activity of 16.4.1 was mapped to a 60 amino acid region and a novel transport signal
identified. Interaction of 16.4.1 with Rev in human cells was shown in a mammalian two-hybrid assay
and by colocalization of Rev and 16.4.1 in nucleoli, indicating that Rev can recruit 16.4.1 to the
nucleus/nucleoli. Rev-dependent reporter expression was inhibited by overexpressing 16.4.1 and
stimulated by siRNAs targeted to 16.4.1 sequences, demonstrating that 16.4.1 expression
influences the transactivation function of Rev.
Conclusion:  These results suggest that 16.4.1 may act as a modulator of Rev activity. The
experimental strategies outlined in this study are applicable to the identification and biological
characterization of further novel Rev-interacting cellular factors.
Background
The human immunodeficiency virus (HIV) Rev protein is
a small (116 amino acids) post-transcriptional activator
of expression of incompletely spliced and unspliced HIV
mRNAs. Since these HIV transcripts direct production of
progeny virions, Rev is a crucial factor in HIV replication
(for overview see [1]). Rev interacts with HIV mRNAs by
binding to a structured RNA element called the RRE (Rev
response element). Rev offsets the activities of inhibitory
sequences (INS) in HIV-1 mRNAs [2,3] and promotes
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their export to the cytoplasm. Once in the cytoplasm, Rev
may also stimulate production of viral proteins on trans-
lational level (reviewed in [4]).
Rev characteristically localizes to the nucleus, where it
accumulates in nucleoli. However, a proportion of the Rev
molecules expressed in a cell continuously shuttles
between nucleus and cytoplasm by using active transport
mechanisms both for entry into and exit from the nucleus.
Mutational analyses of the Rev protein have identified
various functionally important regions, indicating that
Rev is organized into modular domains (Fig. 1A; reviewed
in [5] and [6]). The N-terminal domain of Rev contains an
arginine-rich motif (ARM; amino acids 35 to 50) with
dual functions as a nuclear localization signal (NLS) and
RNA binding domain. Sequences flanking the ARM
(amino acid regions 12 to 29 and 52 to 60) direct mul-
timerization of Rev. The C-terminal domain of Rev, also
known as activation domain, contains a leucine-rich
motif (amino acid region 75 to 83) that functions as a
nuclear export signal.
Biochemical analyses indicate that Rev directly binds the
nuclear transport receptors Importin β  and CRM1/Expor-
tin 1 [7-9]. Interaction of Rev with CRM1/Exportin 1 was
confirmed by two-hybrid assays in yeast [10] and in
human cells [11,12]. Together with results from various
other experimental approaches (reviewed in [6]), these
observations have led to the concept that import of Rev
into the nucleus is mediated by interaction of the ARM/
NLS with Importin   and export of the Rev-RNA complex
from the nucleus by interaction of the Rev-NES with
CRM1/Exportin 1.
Various other Rev-interacting cellular factors have been
identified by using Rev or segments of Rev for yeast two-
hybrid screening of cDNA libraries or for biochemical
purification of interacting factors from cell extracts.
Cellular factors shown to interact with the ARM of Rev
include p32 [13,14] and B23 [15,16]. Human p32 was
recently reported to block splicing of Rev-dependent HIV
transcripts [17]. The nucleolar protein B23 was shown to
stimulate nuclear import of Rev [18] and counteract
aggregation of Rev [19]in vitro.
The C-terminal domain of Rev interacts with various
human nucleoporins, including hRIP/hRab, NLP-1,
Nup98, and Nup214 [20-26]. Other factors shown to
interact with this domain of Rev are eIF-5A [27] and the
nuclear kinesin-like protein REBP [28]. hRIP/hRab, Nup
98 and eIF-5A interact with CRM1 as well as Rev
[10,25,26,29], suggesting that Rev can associate with
CRM1 in multifactorial complexes in which CRM1
"bridges" the interaction of Rev with other factors. Rev-
CRM1 complexes containing hRIP/hRab or eIF-5A may be
crucial for Rev-dependent export of HIV RNAs, since eIF-
5A and hRIP/hRab have been shown to be essential for
Rev-directed RNA export in Xenopus  oocytes and in
human cells, respectively [30,31].
Nuclear export of Rev has proven to be exemplary for
many viral and cellular factors (reviewed in [32,33]).
Since the discovery of leucine-rich signals in Rev [34] and
in the cellular regulatory factor PKIα  [35], these sequences
have been shown to mediate the export of numerous fac-
tors from the nucleus by CRM1/Exportin1 [36]. The drug
Leptomycin B (LMB), first shown to block nuclear export
of Rev [37], proved to be a potent inhibitor of CRM1-
dependent export [38,39] and is now widely used to iden-
tify transport substrates of CRM1. Elucidating interactions
of Rev with cellular factors is highly relevant to under-
standing pathogenicity of HIV and may have an impact on
the design of therapeutic anti-HIV strategies. The func-
tional diversity of Rev and its activities in both nuclear
and cytoplasmic compartments of the cell suggest the
existence of still unidentified Rev-interacting factors.
Therefore we reasoned that screening of a human cDNA
library with Rev as "bait" should lead to isolation of novel
Rev-interacting human factors. Of particular interest
would be the identification of unknown human gene
products, since their interaction Rev would not only be
relevant for Rev function but would also provide a key for
biological characterisation of these novel factors.
Here we identify a human cDNA that encodes a novel pro-
tein (16.4.1) that interacts specifically with Rev via
sequences in the N-terminal half of Rev. We show that
16.4.1 is exported from the nucleus by CRM1 and local-
izes to the cytoplasm. In Rev-expressing cells, 16.4.1 is
recruited to nucleoli. 16.4.1 has a negative effect on Rev
function in a Rev-reporter assay. These results suggest that
16.4.1 can act as a modulator of Rev function.
Results
Identification of novel HIV-1 Rev-interacting proteins
To identify novel Rev-interacting proteins, we screened a
library of cDNAs derived from the human Jurkat T-cell
line with full-length Rev as bait in a yeast two-hybrid sys-
tem. Repeated selection procedures led to isolation of two
library plasmids (11.5.1 and 16.4.1) encoding specific
interactors of Rev.
Sequence analyses and data base comparisons revealed
that the 936 bp insert in plasmid 11.5.1 is identical with
a segment of a 1543 bp cDNA encoding human DNA
binding protein B (dbpB; NCBI accession number
BC002411) [40]. The predicted coding sequences in the
11.5.1 cDNA comprise the C-terminal 139 amino acids of

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Analysis of interaction of 16.4.1 with Rev Figure 1
Analysis of interaction of 16.4.1 with Rev. (A) Schematic overview of domains of Rev. Locations of functional regions are 
taken from [5]. Numbering of amino acids (aa) is based on the Rev sequence of HIV-1 isolate HXB-2. MI and MII: Regions that 
direct multimerization of Rev. NLS: nuclear localization signal; NES: nuclear export signal. (B) Identification of amino acid posi-
tions in Rev required for interaction with 16.4.1. Bait proteins containing Rev or various mutants of Rev were analysed for 
interaction with 16.4.1-prey. Numbers indicate positions of amino acid changes in Rev mutants. Mutations are as follows: 
RevM4: Y23 to D23, S25 to D25, N26 to L26 [45]; Rev M10BL: L78 to D78, E79 to L79 and insertion of EDLP between L81 and T82 [47]; 
Rev M5: R38 to D38, R39 to L39 [45]; RevSLT40: I59 to D59, L60 to D59 [46]. Interaction is indicated by growth of yeast transform-
ants under selective conditions (≥  500 transformants per plate). Results represent four independent experiments. The red box 
marks the amino acid positions in Rev required for interaction with 16.4.1 and the location of the putative 16.4.1-interaction 
region of Rev (aa 38 to 60). (C) Identification of regions of 16.4.1 required for interaction with Rev. Prey proteins containing 
various regions of the 16.4.1 domain were analysed for interaction with Rev-bait. Interaction was analysed by growth of yeast 
transformants under selective conditions. Results represent three independent experiments. +++ 700–1400 transformants per 
plate; + 200–400 transformants per plate; – no transformants. 16.4.1 regions comprising amino acids 2 to 133 and 39 to 171 
interacted with Rev with similar efficiency as full-length 16.4.1, whereas regions 2 to 73 and 74 to 171 showed weaker interac-
tion. No interaction was observed with regions 2 to 38 and 134 to 171. The red arrow indicates the putative Rev-interaction 
region of 16.4.1 (aa 39 to 133).
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the dbpB protein (324 amino acids; NCBI accession
number M24070). Several biological activities have been
attributed to dbpB, including binding to DNA [41] and
RNA [42,43] and regulation of transcription [44].
The other library plasmid 16.4.1 contained a 696 bp insert
of which a region of over 450 nucleotides showed strong
similarity to a sequence within a human fetal heart cDNA
(NCBI accession number W67699). In the fetal heart
cDNA the matching region encompasses a predicted open
reading frame. Alignment of the 16.4.1 and the fetal heart
cDNA sequences yielded a sequence encoding a hypothet-
ical 171 amino acid 16.4.1 protein. Since interaction with
Rev is the first biological activity associated with this gene
product, we analysed interaction of Rev with the 16.4.1
protein in more detail.
To investigate which regions of Rev contribute to interac-
tion with the 16.4.1 protein, we analysed the capacity of
various known mutants of Rev to interact with 16.4.1 in
the yeast two-hybrid assay. The amino acid exchanges in
these mutants map to regions associated with major bio-
logical properties of Rev (Fig. 1B), including multimeriza-
tion (RevM4 [45] and RevSLT40 [46]), RNA binding and
nuclear localization/accumulation (RevM5 [45]) and
nuclear export of Rev (RevM10BL [47]). Expression of
LexA-Rev-mutant bait proteins in yeast transformants was
confirmed by Western blot analysis with polyclonal anti-
bodies against Rev (data not shown). As positive control
for Rev interaction, interaction analysis was performed
with LexA-Rev bait and B42AD-Rev prey, confirming oli-
gomerization of wildtype Rev molecules with each other
(data not shown).
While Rev mutants RevM4 and Rev M10BL were capable
of interacting with 16.4.1, no interaction was observed
with Rev mutants RevM5 and RevSLT40 (Fig. 1B). These
results indicate that amino acid residues R38 or R39 of the
ARM and I59 or L60 of the multimerization region II (MII)
are required for interaction of Rev with the 16.4.1 protein.
Furthermore, they suggest that the 16.4.1 interacting
sequences in Rev are located between aa positions 38 and
60.
For more detailed study of the interaction of the 16.4.1
protein with Rev, yeast two-hybrid analysis was per-
formed with various segments of the 16.4.1 cDNA as prey
and wildtype Rev as bait (Fig. 1C). Amino acid regions of
16.4.1 extending from position 2 to 133 and from posi-
tion 39 to 171 showed similar Rev-binding capacity as
full-length 16.4.1 protein. In contrast, both the N-termi-
nal region (2 to 38) and the C-terminal region (134 to
171) of 16.4.1 failed to interact with Rev. While 16.4.1
protein fragments from position 2 to 73 or position 74 to
171 clearly interacted with Rev, interactions were weaker
than that of full-length 16.4.1. These results indicate that
the Rev-interacting region of the 16.4.1 protein is located
between amino acid positions 39 and 133 and that,
within this region, sequences N- and C-terminal of posi-
tion 73 contribute to interaction with Rev.
Interaction of the 16.4.1 protein with Rev, CRM1 and itself 
in human cells
The interaction of the 16.4.1 protein with Rev in yeast
raises the question whether the 16.4.1 protein can also
interact with Rev in human cells. It was also of interest
whether 16.4.1 is capable of interacting with human
CRM1, since CRM1 has been shown to interact with sev-
eral Rev-associated factors (see Background).
We addressed these issues with a mammalian two-hybrid
assay, in which the interaction of a protein fused to the
Gal4 DNA-binding domain with a second protein fused
to the VP16-activator domain induces transcription of a
luciferase reporter gene from a synthetic promoter (for
details see Materials and Methods). Rev was fused to VP16
(VP16-Rev) to avoid unspecific interactions between the
acidic VP16 domain [48] and the basic Rev protein (esti-
mated pI = 9.93; MacVector calculation). Functionality of
VP16-Rev was demonstrated (data not shown) in a Rev-
reporter assay [3]. For interaction analysis, HEK293 cells
were cotransfected with expression plasmids for VP16-Rev
and Gal4-16.4.1 fusion proteins and the reporter plasmid
pG5luc. As shown in Fig. 2, a ≈ 11-fold mean induction of
luciferase activity was observed in 14 independent trans-
fection experiments. Assessment of interaction of 16.4.1
with human CRM1 in cells coexpressing Gal4-16.4.1 and
VP16-hCRM1 revealed a ≈ 41-fold mean induction of luci-
ferase activity export (n = 7) (Fig. 2). Self-interaction of
the 16.4.1 domain was analysed by coexpressing Gal4-
16.4.1 and VP16-16.4.1, resulting in ≈ 12-fold mean
induction of luciferase activity (n = 6).
In all three cases, induction of luciferase activity was sig-
nificantly (p < 0.04) increased over induction levels
obtained in control assays with unfused VP16 and Gal4-
16.4.1 (3.3-fold; n = 7).
These results indicate that the 16.4.1 domain is capable of
interacting with Rev as well as with the export receptor
CRM1 and of forming homo-oligomers in human cells.
Cytoplasmic localization of 16.4.1 is CRM1/Exportin 1 
dependent
Comparison of the sequence in the 16.4.1 cDNA with the
fetal heart cDNA indicated that the 16.4.1 sequence was
incomplete at its 5' terminus. To generate a full-length
(171 aa) 16.4.1 coding sequence, nucleotides encoding
the first 8 N-terminal amino acids derived from the
predicted open reading frame of the fetal heart cDNA wereBMC Cell Biology 2005, 6:20 http://www.biomedcentral.com/1471-2121/6/20
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inserted upstream of the 16.4.1 cDNA. To analyse subcel-
lular localization of the 16.4.1 protein, cells were trans-
fected with plasmids directing expression of fusion
proteins containing full-length 16.4.1 or various segments
of 16.4.1. Those fusion proteins contained either a N-ter-
minal IgG1 tag or a C-terminal GFP tag. The full-length
IgG1-16.4.1 fusion protein (IgG1-2-171) was located
mainly in the cytoplasm of HeLa cells (Fig. 3A). IgG1
fusion proteins with 16.4.1 regions extending from amino
acid position 2 to 133, 39 to 171 and 74 to 171 showed
similar predominantly cytoplasmic localization (Fig. 3A).
In contrast, IgG1 fusion proteins with the N-terminal
region (2 to 38) or the C-terminal region (134 to 171) of
16.4.1 were apparent in both nucleus and cytoplasm, sim-
ilar to unfused IgG1. These results demonstrate that the
16.4.1 protein is capable of cytoplasmic accumulation
and suggest that sequences directing cytoplasmic localiza-
tion of the 16.4.1 protein are located between amino acid
positions 74 to 133.
The 16.4.1-GFP fusion protein showed similar cytoplas-
mic localization as IgG1-16.4.1 (Fig. 3B). Quantitative
evaluation of subcellular distribution of GFP fluorescence
[49] revealed that only 25% of total fluorescence was con-
tained in the nuclei of 16.4.1-GFP expressing cells. This
localization is comparable to that of GFP fusion proteins
Interaction of 16.4.1 with HIV-1 Rev, hCrm1 and with itself in human cells Figure 2
Interaction of 16.4.1 with HIV-1 Rev, hCrm1 and with itself in human cells. 16.4.1 interactions in human cells were 
analysed with a mammalian two-hybrid assay in which the interaction of a protein fused to the Gal4 DNA-binding domain with 
a second protein fused to the VP16-activator domain induces transcription of a luciferase reporter gene. HEK293 cells were 
cotransfected with pBIND-16.4.1 plasmid for expression of Gal4-16.4.1 fusion protein, a pACT plasmid for expression of the 
indicated VP16-fusion protein and with the pG5luc reporter plasmid. Parallel cultures were cotransfected with pG5luc and the 
pBIND and pACT vectors to determine basal expression of the luciferase gene. Cells were lysed 48 hours after transfection 
and luciferase activities determined. Bars indicate the mean fold- induction of luciferase activity over basal expression ± SEM 
(standard error of the mean) and represent at least 6 independent transfection experiments. Cells coexpressing Gal4-16.4.1 
and VP16 fused with Rev (grey bar), hCRM1 (black bar) or 16.4.1 (vertically striped bar) domains showed significantly stronger 
induction of luciferase production than cells coexpressing Gal4-16.41 and unfused VP16 (diagonally striped bar). Statistical anal-
ysis was performed by two-tailed Mann-Whitney U test.
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CRM1-dependent cytoplasmic localization of 16.4.1 Figure 3
CRM1-dependent cytoplasmic localization of 16.4.1. HeLa cells were transfected with plasmids directing expression of 
IgG1-16.4.1 or 16.4.1-GFP fusion proteins and subcellular distribution of tagged proteins analysed 24 hours later in fixed cells. 
(A) Subcellular distribution of IgG1 fusion proteins containing full length 16.4.1 or various segments of 16.4.1. IgG1-16.4.1 pro-
teins were detected by immunocytochemistry with a Cy3-conjugated anti human IgG1 antibody. A schematic diagram of the 
IgG1-16.4.1 fusion proteins and a summary of their localization behavior are shown at the top. Representative images of cells 
expressing IgG1 fusion proteins containing the indicated amino acid regions of 16.4.1 are shown below. IgG1 fusion proteins 
containing amino acids 2–171 (full-length), 2–133, 39–171 and 74–171 of 16.4.1 were predominantly cytoplasmic, whereas 
fusion proteins with amino acids 2–38 or 134–171 and unfused IgG1 were both cytoplasmic and nuclear. Scale bars: 20 µm. (B) 
Disruption of predominantly cytoplasmic localization of 16.4.1-GFP by treatment of cells with the CRM1-inhibitor Leptomycin 
B (LMB). HeLa cells were transiently transfected with plasmids for expression of 16.4.1-GFP, PKIα -GFP, Rev(52–116)-GFP and 
unfused GFP. Cells were treated with LMB (5 nM) for two hours. Representative images of the subcellular distribution of the 
GFP fusion proteins in untreated (-) and LMB treated cells (+) are shown at the top. Symbols in the graph indicate the nuclear 
proportion of fluorescence (%) in individual cells and horizontal lines and numbers the median of the cell population. LMB 
treatment increased the median nuclear proportion of 16.4.1-GFP from 25% to 44%. LMB had a similar effect on localization of 
GFP fusion proteins containing PKIα  or the carboxyterminal region of Rev (aa 52–116), which are known transport substrates 
of CRM1. In contrast, LMB only marginally affects subcellular distribution of unfused GFP. Scale bars: 10 µm.
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containing PKIα  (PKIα -GFP) or the carboxyterminal half
of Rev (Rev(52–116)-GFP), which localize to 23% and
25%, respectively, in the nucleus (Fig. 3B). PKIα  and the
carboxyterminal half of Rev contain well-characterized
recognition signals for CRM1/Exportin 1-dependent
export [36]. Similar cytoplasmic localization of 16.4.1-
GFP and interaction of 16.4.1 with CRM1/Exportin 1 in
human cells (Fig. 2) raised the possibility that cytoplasmic
localization of 16.4.1-GFP at steady state may involve
nuclear export of 16.4.1 by CRM1/Exportin 1. Therefore
we analysed the effect of Leptomycin B (LMB), an inhibi-
tor of CRM1-dependent nuclear export [11,37,38] on sub-
cellular distribution of 16.4.1-GFP. LMB treatment
significantly increased the nuclear proportion of 16.4.1-
GFP from 25% to 44%. LMB-induced nuclear redistribu-
tion was similar in cells expressing PKIα -GFP and Rev(52–
Analysis of CRM1-dependent nuclear export of amino acid region 74 to 133 of 16.4.1 Figure 4
Analysis of CRM1-dependent nuclear export of amino acid region 74 to 133 of 16.4.1. HeLa cells were transfected 
with plasmids directing expression of GFP fusion proteins containing 16.4.1 region 74–133 in single copy or in tandem (74–
133)2. Representative images of the subcellular distribution of the GFP fusion proteins in untreated (-) and LMB treated cells 
(+) are shown at the top. Symbols in the graph indicate the nuclear proportion of fluorescence (%) in individual cells and hori-
zontal lines and numbers the median of the cell population. Scale bars: 10 µm. Inhibition of CRM1 by LMB treatment increases 
nuclear proportion of GFP fusion proteins containing aa residues 74 to 133 of 16.4.1. GFP fusion proteins containing two cop-
ies of region 74 to 133 show stronger cytoplasmic localization than GFP fusion proteins with a single copy. These results indi-
cate that region 74 to 133 of 16.4.1 is a substrate for CRM1-dependent export, which is recognized more efficiently in tandem 
than as a single copy.
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116)-GFP, whose nuclear proportion increased to 49%
and 46%, respectively. Quantitative analysis demon-
strated that 45% of unfused GFP localized to the nucleus,
in agreement with its known capacity to diffuse through-
out the cell [50]. LMB had no significant effect on subcel-
lular distribution of unfused GFP.
These results indicate that cytoplasmic localization of
16.4.1 involves nuclear export by CRM1/Exportin1.
Amino acid region 74 to 133 of 16.4.1 seems to be crucial
for those transport processes.
Identification of a candidate nuclear export signal in 
16.4.1
To further characterize the involvement of the amino acid
region 74–133 in cytoplasmic localization of 16.4.1, we
assessed subcellular distribution of GFP fusion proteins
containing this region of 16.4.1. Cells expressing a GFP
fusion protein with a single copy of aa 74–133 of 16.4.1
contained a higher proportion of nuclear fluorescence
(38%, Fig. 4) than cells expressing GFP fusion proteins
with full-length 16.4.1 (25%, Fig. 3B). However, GFP-
fusion proteins containing two copies of region 74 to 133
of 16.4.1 in tandem showed similar cytoplasmic localiza-
tion (Fig. 4; 27% nuclear proportion) as full-length
16.4.1-GFP (Fig. 3B; 25%). Treatment of cells with LMB
raised nuclear proportions of GFP fusion proteins with
one or two copies of 16.4.1 region 74–133 to similar
levels as full-length 16.4.1-GFP. These results suggest that
the region between amino acid positions 74 and 133 con-
tains a CRM1/Exportin 1 dependent nuclear export signal,
which can act in a cumulative manner.
Examination of the hypothetical amino acid sequence of
region 74 to 133 revealed a clustering of leucine and iso-
leucine residues between amino acid 86 and 105 (Fig. 5A,
shaded in grey). To analyse whether region 86 to 105 of
the 16.4.1 protein functions as a nuclear export signal, we
compared its translocation capacities with the Rev-NES in
a previously described microinjection assay [51] (Fig. 5B).
In this assay, peptides bearing the candidate transport
sequences are linked to fluorescently labeled bovine
serum albumin (BSA). These potential transport sub-
strates are coinjected into the nucleus with unlinked BSA
labeled with a different fluorescent color that serves as
injection control. Two hours later, cells are fixed and the
percentage of each fluorescent label in the nuclear com-
partment of individual cells determined. The relative
translocation activity signifies the ratio of fluorescence of
the transport substrate to the fluorescence of the injection
control. Selective export of the transport substrate from
the nucleus yields relative translocation activities < 1, as
demonstrated for a transport substrate containing the NES
of Rev (Fig. 5B and [51]). A substrate containing the
16.4.1-derived sequence also yielded a relative
translocation activity < 1 (Fig. 5B). These results indicate
that region 86 to 105 of 16.4.1 sequence can function as a
nuclear export signal.
To further characterize this nuclear export signal in 16.4.1
we took advantage of a collection of weight matrices (M1-
M7) derived for recognition of NES by bioinformatics
(Blossom similarity matrix). These matrices recognized 48
out of 75 signals of a published NES database [36] at a
default threshold of 0.84 in the context of their native pro-
teins. No match was obtained upon scanning of the
16.4.1 amino acid sequence with these matrices at default
threshold. This indicates that the 16.4.1 sequence is dis-
tinct from the 48 NES represented by the matrices. How-
ever, rescanning of the 16.4.1 sequence at a lower
threshold (0.74) yielded a single match for matrix M5
(0.78), comprising amino acids 92–99 of 16.4.1 (core
NES). At default threshold the same matrix recognized a
specific group of NES that includes the NES of Stat1 and
p65RelA (Fig. 6A). However this matrix did not recognize
the NES of PKIα  or Rev, which were recognized by differ-
ent matrices. An artificial 16.4.1 NES sequence containing
leucine instead of isoleucine residues at positions 99 and
101 was recognized by matrix M5 above default score
(0.86) but by no other matrices, even at reduced
thresholds.
Finally we investigated whether the candidate transport
signal also shows nuclear export activity in the context of
the complete 16.4.1 protein. As shown in figure 6B, the
leucine and two isoleucine residues of the 16.4.1 core NES
were changed to Alanin and the subcellular distribution of
the 16.4.1(NESmut)-GFP was compared to the wildtype
16.4.1 fused to GFP. The mutant 16.4.1-GFP fusion pro-
tein localized to significantly higher levels in the nucleus
than wildtype 16.4.1-GFP (34% versus 27%). However,
the nuclear proportion of the mutant 16.4.1-GFP
remained below that of unfused GFP (Fig. 3B), indicating
residual nuclear export of the mutant 16.4.1-GFP.
In summary, combined computational and functional
analyses indicate that amino acid residues 86 to 105 act as
a nuclear export signal, with amino acids 92 to 99 consti-
tuting a potential core NES. Mutational analysis indicates
that the leucine/isoleucine of the 16.4.1 core NES contrib-
ute to but are not sole determinants of cytoplasmic local-
ization of 16.4.1.
Colocalization of 16.4.1 and Rev
This report demonstrates interaction of 16.4.1 and Rev in
yeast and mammalian two-hybrid assays (Figs. 1 and 2).
In these approaches, candidate interaction partners are
artificially targeted to the nucleus to measure interaction-
dependent reporter gene expression.BMC Cell Biology 2005, 6:20 http://www.biomedcentral.com/1471-2121/6/20
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Functional analysis of a nuclear export signal in 16.4.1 Figure 5
Functional analysis of a nuclear export signal in 16.4.1. (A) Depicted is the sequence (nucleotides and predicted amino 
acids) of the 16.4.1 protein investigated here. The sequence encoding amino acids 1–8 are derived from the fetal heart cDNA 
W67699. The region between amino acid residue 74 and 133 showing CRM1-dependent nuclear export activity (Fig. 4) is 
underscored. The amino acid sequence between residues 86 and 105 (shaded in grey) contains several Leucine and Isoleucine 
residues representing a candidate nuclear export signal. (B) Functional characterisation of the Leucine-Isoleucine rich sequence 
of 16.4.1. Comparison of the translocation activities of 16.4.1 region 86–105 and the Rev-NES in a microinjection-based trans-
port assay [51]. Transport substrates were generated by conjugating peptides containing region 86–105 of 16.4.1 or region 73–
84 of Rev with bovine serum albumin (BSA) labeled with a red fluorescent dye. Transport substrates were coinjected into the 
nucleus with an injection control consisting of unconjugated BSA labeled with a different fluorescent dye (e.g. green). The pro-
portion of each fluorescent label in the nucleus of the injected cell was determined and the ratio of fluorescence of the trans-
port substrate to fluorescence of the injection control calculated. This ratio represents the relative translocation activity of the 
transport substrate and is indicated in the graph. Nuclear export activity yields ratios <1 as demonstrated for the Rev NES. 
Transport substrates containing amino acid region 86–105 of 16.4.1 also yielded a relative translocation activity <1, indicating 
that this region of 16.4.1 can function as a nuclear export signal.
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To analyse whether 16.4.1 and Rev interact under condi-
tions in which they retain their natural localization behav-
ior, we analysed cells coexpressing 16.4.1 and Rev for
colocalization of both proteins.
To this end, we first established a HeLa cell line stably
expressing 16.4.1-GFP and a corresponding control cell
line expressing unfused GFP. The expression of 16.4.1-
GFP for more than 20 passages did not affect cell growth
monitored by measurement of growth curves and did not
lead to cell toxicity detectable as release of lactate dehy-
drogenase (LDH) or ATP into cell culture supernatants
(data not shown). Furthermore, long-term expression did
not alter the predominantly cytoplasmic localization of
16.4.1-GFP.
Influence of the nuclear export signal on cytoplasmic localization of 16.4.1 Figure 6
Influence of the nuclear export signal on cytoplasmic localization of 16.4.1. (A) Sequences identified in 16.4.1 and in 
proteins contained in a database of experimentally verified NES by a common weight matrix. Protein sequences in NESbase 
version 1 [36] were analysed with a collection of 7 weight matrices. These identified 48 of 75 NES in their native protein con-
text at default threshold (0.84). Analysis of the 16.4.1 sequence with reduced threshold settings (0.74) yielded a single match 
with matrix M5 but not with any other matrix. This match identified the 16.4.1 core NES (shown at top). Sequences in proteins 
of the NES database identified by M5 at default threshold are shown below. All sequence matches map to experimentally veri-
fied NES. (B) To assess functionality of the novel 16.4.1 NES in the context of the full length protein, a 16.4.1 mutant was gen-
erated in which L92, I97 and I99 were replaced by alanine residues. HeLa cells were transfected with plasmids for expression of 
GFP fusion proteins containing wild type (16.4.1-GFP) or mutated (16.4.1(NESmut)-GFP) 16.4.1 and subcellular distribution of 
GFP fusion proteins were evaluated by quantitative fluorescence microscopy. Cells expressing 16.4.1(NESmut)-GFP showed a 
significantly higher nuclear proportion of fluorescence (34%) than cells expressing wild type 16.4.1-GFP (27%). This effect was 
significant (p < 0.005). Scale bars: 10 µm.
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For colocalization studies, HeLa 16.4.1-GFP cells and con-
trol HeLa-GFP cells were transfected with a plasmid direct-
ing expression of Rev-CFP (cyan fluorescent protein)
fusion proteins. Transfected cells were subjected to epiflu-
orescence microscopy and Z-stacks were collected. Images
were processed by deconvolution and multichannel
unmixing, allowing separate evaluation of the spatial dis-
tribution of GFP and CFP signals. Over 25 cells were ana-
lyzed. Multichannel unmixing is a recently developed
technique for separate detection of fluorochromes that
exhibit significant spectral overlap in conventional
fluorescence microscopy setups, such as CFP and GFP (for
a review see [52]). Fig. 7A shows examples of cells express-
ing 16.4.1-GFP either alone (white arrow) or together
with Rev-CFP (red arrow). 16.4.1-GFP was only visible in
the nucleoli of cells co-expressing Rev-CFP but not in cells
lacking Rev-CFP (see also Fig. 3). Cells coexpressing
16.4.1-GFP and Rev-CFP showed stronger nucleoplasmic
GFP fluorescence than HeLa 16.4.1-GFP cells lacking Rev-
CFP. Rev-CFP retained typical nuclear/nucleolar localiza-
tion [49] when coexpressed with 16.4.1-GFP, indicating
that 16.4.1-GFP does not influence localization of Rev-
CFP. Control imaging of HeLa cells expressing GFP either
alone (Fig. 7B, top panel) or together with Rev-CFP (Fig.
7B, bottom panel) showed that presence of Rev-CFP did
not influence the GFP signal and that the CFP signal was
apparent only in cells expressing Rev-CFP. These results
verified separation of Rev-CFP and GFP signals by the
multichannel unmixing routine and confirmed that the
CFP-tag in Rev-CFP does not affect localization of GFP.
These results indicate that Rev is capable of directing
16.4.1 to nucleoli and provide further evidence for inter-
action of Rev and 16.4.1 in human cells.
Influence of 16.4.1 on Rev functions
To investigate the influence of 16.4.1 on Rev function, we
analysed the effect of IgG1-16.4.1 and 16.4.1-GFP fusion
proteins on transactivation capacity of Rev using a
previously described Rev-reporter assay [3]. The mRNA
synthesized from the reporter gene in this assay contains
a region coding for red fluorescent protein (RFP) and a
non-coding region with HIV-1 derived sequence elements
mediating Rev-responsiveness. These consist of multiple
INS from the HIV-1 gag gene and the RRE from the HIV-1
env gene. Rev activity is measured by quantification of RFP
reporter positive cells by flow cytometry using the gating
strategy depicted in Fig. 8A (for further details see figure
legend). Experiments were performed in 293T cells
because of the high transfection efficiencies achieved in
these cells.
The transactivation capacity of Rev in the absence of exog-
enous 16.4.1 was set at 100%. The result of 5 independent
experiments demonstrate an approximately 50%
reduction of Rev activity by coexpression of 16.4.1 fusion
proteins (Fig. 8A). A dose-dependent effect of 16.4.1-GFP
expression on Rev activity was observed (Fig. 8B). No
effect was observed for numerous other gene products of
a human cDNA-library tested in this assay (Wolff et al,
manuscript in preparation).
In the experiment above we showed that overexpression
of 16.4.1-GFP exhibited a negative effect on the transacti-
vation capacity of HIV-1 Rev in human cells. Isolation of
16.4.1 from a human cDNA library suggests that 16.4.1
proteins may be produced in human cells. To target
expression of native 16.4.1 we decided to use RNA inter-
ference. To identify inhibitors of 16.4.1 expression we
analysed several candidate siRNAs targeted to sequences
within the 16.4.1 coding region and a negative control
siRNA that recognizes sequences located upstream of the
16.4.1 coding region. An exemplary experiment is shown
in Fig. 9A, B. HeLa 16.4.1-GFP cells were transfected with
siRNAs and the effects on expression of 16.4.1-GFP mon-
itored by flow cytometry (Fig. 9A and 9B). 16.4.1-GFP
expression levels in RNAi transfected cells were deter-
mined relative to those in untransfected cells in 40.000
cells by FACS analysis. siRNA-16.4.1 reduced mean rela-
tive expression levels of 16.4.1-GFP to 36%. A similar
effect was observed for a positive control siRNA that
silences GFP (data not shown). The negative control
siRNA (siRNA-nsp) only moderately diminished mean rel-
ative expression of 16.4.1-GFP to 81%. A similarly moder-
ate reduction was observed for mock-transfected cells
(data not shown) indicating that this is caused by the RNA
transfection procedure. Analysis of the inhibitory effect of
siRNA-16.4.1 on 16.4.1-GFP expression in three addi-
tional experiments yielded a mean relative expression of
16.4.1-GFP of 30.7% + 4.7 (standard deviation), confirm-
ing the inhibitory effect of this siRNA on 16.4.1-GFP.
Subsequently we investigated the effect of siRNA-16.4.1
and the negative control siRNA-nsp in 293T cells in the
Rev-reporter assay described above (Fig. 9C). The negative
control siRNA (siRNA-nsp) had no effect on Rev transacti-
vation capacity compared to mock transfected cells (1%
increase of Rev activity). In contrast, siRNA-16.4.1
increased Rev transactivation capacity by 17% compared
to mock-transfected controls. A specific enhancing effect
of siRNA-16.4.1 was observed in three independent exper-
iments. These results indicate that endogenous 16.4.1
gene products are capable of modulating Rev activity.
Expression of 16.4.1 proteins
Database searches identified several cDNAs of various
lengths that contain the complete 16.4.1 sequence within
a predicted open reading frame [For overview see addi-
tional file 1: Figure A1 and additional file 2: Table A1].
These are derived from various human tissues and cells.BMC Cell Biology 2005, 6:20 http://www.biomedcentral.com/1471-2121/6/20
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Nucleolar colocalization of 16.4.1-GFP and Rev-CFP Figure 7
Nucleolar colocalization of 16.4.1-GFP and Rev-CFP. HeLa 16.4.1-GFP cells and control HeLa GFP cells were tran-
siently transfected with a Rev-CFP expression plasmid. Nuclei were counterstained with Hoechst 33342. 3D-Maximum image 
projections of Z-stacks were deconvolved and processed by multichannel unmixing, applying identical parameters to all images 
(see Material and Methods). Left images represent the GFP-channel (green), middle images the CFP-channel (pseudocolored 
red) and right images either an interference contrast photo (A) or a single z-slice of a phase contrast image (B). (A) Exemplary 
images of over 25 analyzed cells demonstrating nucleolar colocalization of 16.4.1-GFP and Rev-CFP. The left image shows 
HeLa-16.4.1-GFP cells either without Rev-CFP (white arrow), or with concurrent Rev-CFP expression (red arrow). The nucle-
olar 16.4.1-GFP signal is only visible in cells coexpressing Rev-CFP. Cells with extremely high expression levels of Rev-CFP 
were excluded from analysis. Scale bars: 10 µm. (B) Controls for separation of GFP and CFP and signals by multichannel unmix-
ing. Images of HeLa cells stably expressing GFP (HeLa-GFP) either alone or together with Rev-CFP are shown in the upper and 
lower panels, respectively. The intracellular distribution of the GFP signal is not influenced by coexpression of Rev-CFP. Con-
versely, a nuclear/nucleolar CFP signal is detected only in HeLa-GFP cells coexpressing Rev-CFP. These results confirm that 
multichannel unmixing eliminates spectral crosstalk between CFP and GFP channels. Scale bars: 10 µm.
Phase contrast  16.4.1-GFP Rev-CFP A)
B) Rev-CFP GFP DICBMC Cell Biology 2005, 6:20 http://www.biomedcentral.com/1471-2121/6/20
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16.4.1 influences transactivation capacity of Rev in human cells Figure 8
16.4.1 influences transactivation capacity of Rev in human cells. Panel (A) depicts the reduction of Rev activity 
obtained by cotransfection of 0.5 µg plasmids directing expression of 16.4.1 fusion proteins and 0.1 µg rev expression plasmids. 
The graph shows mean values and standard deviations of 5 independent experiments carried out in 293T cells expressing 
either IgG1-16.4.1 or 16.4.1-GFP in combination with Rev-GFP or Rev-CFP. FACS analysis was used to quantify the number of 
cells expressing the Rev-dependent RFP reporter encoded by pLRed(INS)2R (see Material and Methods) within the population 
of transfected cells. The dot plots above the bars (FL1 = green fluorescence, FL3 = red fluorescence) represent examples for 
evaluation of FACS data for fully functional Rev (left), inhibited Rev function by 16.4.1 coexpression (middle) and background 
expression of the reporter in the absence of Rev (right). The non-transfected, fluorescence negative 293T cell population is 
represented in grey and excluded from analyses. 293T cells containing the inactive reporter gene (no red fluorescence) and 
expressing GFP as transfection control were used to define the transfected cell population (R2, right dot plot). Cells trans-
fected with all plasmids required for activation of reporter gene expression (expression plasmids encoding Rev, Tat and the 
reporter RFP) as well as for expression of the GFP transfection control contain a population of cells expressing both green and 
red fluorescent proteins defined as R3. The ratio of R3 to R2 represents the proportion of transfected cells showing Rev-
dependent reporter expression (i.e. Rev activity). Rev activity in the absence of 16.4.1 was set at 100% (left bar of the graph). 
Coexpression of 16.4.1 fusion proteins diminished Rev activity to approximately 50% (middle bar). (B) The graph shows the 
result of a single experiment analysing the effect of different amounts of 16.4.1-GFP expression on Rev-CFP activity. Rev-CFP 
activity in the absence of 16.4.1-GFP was set at 100%. Coexpression of different amounts of 16.4.1-GFP reduced Rev activity to 
35.1% (0.5 µg pC16.4.1sg143) or 12.8% (1 µg pC16.4.1sg143) demonstrating a dose dependent effect of the 16.4.1-GFP on Rev 
activity.
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Influences of endogenous 16.4.1 proteins on transactivation capacity of Rev in human cells Figure 9
Influences of endogenous 16.4.1 proteins on transactivation capacity of Rev in human cells. (A and B) Downregu-
lation of 16.4.1-GFP expression in HeLa cells by siRNAs. HeLa cells stably expressing 16.4.1-GFP were transfected with a pre-
synthesized siRNA directed against a 16.4.1 specific sequence (siRNA-16.4.1) or a non-specific siRNA (siRNA-nsp). Expression 
of 16.4.1-GFP was quantified by flow cytometry in 40.000 cells. Panel A shows an overlay of GFP-expressing cell populations in 
untransfected cells (green curve) and after transfection with the 16.4.1-specific siRNA (blue) and the non-specific (red). 16.4.1-
GFP expression in untransfected cells was set at 100% and the percentage of down regulation of green fluorescence indicated. 
siRNA-16.4.1 reduced expression levels of GFP-tagged 16.4.1 to 36% which was similar to the silencing effect of si-GFP which 
was analyzed as control (not shown). Higher levels of 16.4.1-GFP expression (81%) were observed in cells transfected with the 
unspecific siRNA-nsp. (C) Enhancement of Rev transactivation capacity by siRNAs targeted against 16.4.1. 293T cells were 
transfected with siRNA-16.4.1 or siRNA-nsp and Rev activities compared with mock-transfected cells (i.e. cells treated with 
the RNAi transfection reagent lacking RNA). Transfection of siRNA-16.4.1 increased Rev activity by 17% whereas the unspe-
cific siRNA-nsp increased Rev activity by only 1%.
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The predicted molecular masses of the hypothetical pro-
teins encoded by these cDNAs range from ~145 kDa to
18.5 kDa. This suggests existence of several human 16.4.1
protein species encoded by various cDNAs, rather than a
single 16.4.1 protein generated from a single cDNA.
Production of 16.4.1 proteins has not been reported so far
and is currently under investigation in our laboratory
(Kramer-Hämmerle et al., in preparation). In the context
of this ongoing study, a monoclonal antibody (Mab) was
generated against recombinant 16.4.1. Indirect immun-
ofluorescence of HeLa cells transfected with the IgG1-
16.4.1 expression plasmid revealed a cytoplasmic staining
pattern that was indistinguishable from that obtained
with antibodies against IgG1 [see additional file 3: Figure
A2, A) a, for image]. The 16.4.1 Mab, but not the second-
ary antibody, also stained untransfected HeLa cells, yield-
ing a cytoplasmic, granular pattern [see additional file 3,
Figure A2, A) b for image]. In Western Blot analysis of
HeLa-16.4.1-GFP cells, the 16.4.1 Mab recognized a band
with the predicted molecular mass of ~45 kDa for the
16.4.1-GFP fusion protein as well as additional proteins
[see additional file 3, Figure A2, B]. These results confirm
specific recognition of 16.4.1 antigens by the 16.4.1 Mab
and indicate expression of endogenous 16.4.1 proteins.
The 16.4.1 Mab has also been used to analyze cells from
different lines and primary tissues, including brain and
peripheral blood mononuclear cells. A staining pattern
similar to that in HeLa cells was observed for 4 out 5 cell
lines analyzed by indirect immunofluorescence (not
shown). Western blot pagesanalysis of the cell lines/tis-
sues investigated so far yielded a total of 4 distinct bands,
ranging in size from > 150 kDa to < 30 kDa [for summary
see additional file 3, Table A2]. The occurrence of these
bands depended on the cell line/tissue investigated. These
results confirm expression of 16.4.1 proteins in human
cells and tissues and suggest cell-specific expression pat-
terns of 16.4.1 proteins.
Future studies are directed at identifying the full range of
16.4.1 protein species with a panel of antibodies and char-
acterizing 16.4.1 expression patterns on cDNA and pro-
tein levels in various cell types.
Discussion
In this study we identified a cDNA encoding a novel cellu-
lar gene product (16.4.1) that interacts with the HIV-1 Rev
protein in yeast and mammalian cells. In human cells,
16.4.1 is a substrate for CRM1-dependent export and
shows predominant cytoplasmic localization. Colocaliza-
tion of Rev and 16.4.1 was observed in nuclei, particularly
in the nucleoli, of cells expressing both proteins.
Overexpression and RNAi experiments indicate that
16.4.1 can influence transactivation function of Rev.
Comparison of cytoplasmic localization properties of 
16.4.1, Rev and PKI
We demonstrate that 16.4.1 interacts with CRM1 (Fig. 2)
and shows similar Leptomycin B sensitive, cytoplasmic
localization behaviour as PKIα  and the carboxyterminal
half of Rev (Fig. 3B) which are known substrates for
CRM1-dependent export [53]. These results indicate that
cytoplasmic localization of 16.4.1 involves CRM1-medi-
ated nuclear export.
A nuclear export signal was mapped in 16.4.1 (Fig 5).
Mutation of the Leucine/Isoleucine residues of the 16.4.1
NES only partially inhibited nuclear export of full-length
16.4.1, whereas leucine/isoleucine residues in the NES
have been shown to be essential for export of Rev and
PKIα  [35,53]. This suggests differences in the export func-
tions of the 16.4.1 NES and the NES of Rev and PKIα . This
conclusion is supported further by the bioinformatics
analysis, which showed that the group of NES sequences
recognized by the same matrix as the 16.4.1 transport sig-
nal did not include the NES of Rev or PKIα  (Fig. 6).
GFP fusion proteins containing a single copy of the 16.4.1
NES showed weaker cytoplasmic localization than GFP
fusion proteins with tandem copies of this region or full-
length 16.4.1-GFP (Fig. 4). This suggests that cytoplasmic
localization of 16.4.1 does not depend solely on the func-
tionality of a single copy of the 16.4.1 NES. The formation
of homo-oligomers of 16.4.1, as shown by mammalian
two-hybrid analysis (Fig. 2), could allow cooperative
activity of multiple 16.4.1 NES. In addition, sequences
beyond the NES could also contribute to cytoplasmic
localization, for example by increasing cytoplasmic reten-
tion of 16.4.1. Sequences beyond the NES of 16.4.1 could
also promote interactions with export-enhancing co-fac-
tors, several of which have been identified so far. These
include the Ran-binding protein 3 (RanBP3) [54,55],
NXT1 [56] and eukaryotic initiation factor 5A (eIF-5A).
eIF-5A was demonstrated to be involved in export of Rev-
like NES but not of the PKIα -NES [30,57], suggesting the
existence of substrate-specific export cofactors. Future
studies will be directed at identifying cellular interaction
partners of the 16.4.1 protein and investigating their
influence on its export activity.
Interactions of 16.4.1 and Rev
In this study we show that 16.4.1 and Rev are capable of
influencing biological properties of one another.
In cells expressing 16.4.1 and Rev, Rev can alter localiza-
tion properties of 16.4.1 by recruiting 16.4.1 to the
nucleus, in particular nucleoli. This is shown by
colocalization of Rev and 16.4.1 in the nucleoli of cells
expressing both proteins (Fig. 7). Cytoplasmic localiza-
tion of 16.4.1 suggests that 16.4.1 interacts with Rev in theBMC Cell Biology 2005, 6:20 http://www.biomedcentral.com/1471-2121/6/20
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cytoplasm and is then translocated together with Rev to
the nucleus and to nucleoli. The region of 16.4.1 that
mediates interaction with Rev (amino acids 39–133, Fig.
1) contains the 16.4.1 NES (amino acids 86–105). Thus
CRM1 could "bridge" interaction of 16.4.1 with Rev.
CRM1-mediated interaction with Rev has been observed
for several cellular proteins proposed to function as cofac-
tors for nuclear export of Rev (see Background). However,
amino acid positions of Rev essential for interaction with
16.4.1 are located outside the Rev NES, and an export-
deficient NES-mutant of Rev (RevM10Bl) was capable of
interacting with 16.4.1 (Fig. 1). This suggests that 16.4.1
does not function as an essential cofactor for nuclear
export of Rev.
We have demonstrated that overexpression of 16.4.1
inhibits transactivation function of Rev (Fig. 8). The
molecular mechanism underlying this inhibitory effect is
unclear. A possible model to explain an inhibitory effect
of 16.4.1 on Rev activity is that 16.4.1 recruited to nucleoli
by Rev promotes association of Rev and CRM1 in inactive
complexes. The strong interaction of 16.4.1 with CRM1
may increase the amount of CRM1 associated with Rev to
inhibitory levels. In support of this model, experimental
evidence has been obtained demonstrating that (1) Rev
associates with CRM1 in nucleoli, influencing its
mobility, (2) high levels of CRM1 inhibit Rev activity and
(3) Rev is capable of recruiting other CRM1-interacting
factors to nucleoli that are capable of inhibiting Rev activ-
ity [26,58,59]. This model will be investigated in future
experiments.
The RNAi experiments suggest that endogenously
expressed 16.4.1 gene products can also affect Rev func-
tion. As expected, the stimulatory effect of RNAi-mediated
inhibition of 16.4.1 expression was small, since Rev is
known to function efficiently in 293T cells [60]. We
attempted to study the long-term effect of inhibition of
endogenous 16.4.1 on Rev function by establishing cell
lines stably expressing siRNA against 16.4.1. However,
this approach was not feasible because of cell death after
2–3 weeks of expression of 16.4.1 siRNAs. This indicates
that 16.4.1 gene products are crucial for cell viability. On
the other hand, overexpression of 16.4.1 is well tolerated
as demonstrated by the establishment of a cell line stably
expressing 16.4.1-GFP.
The physiological role of interaction of Rev with 16.4.1 is
not clear yet and may be positive or negative, depending
on the levels of expression of 16.4.1. At low levels 16.4.1
proteins may act as a molecular chaperones of Rev,
counteracting the strong tendency of Rev to aggregate with
itself and/or preventing incorrect interactions with other
cellular proteins. The occurrence of cytoplasmic cellular
factors that inhibit Rev multimerization is suggested by a
recent report demonstrating only weak Rev-Rev interac-
tion in the cytoplasm of living cells [61]. At high concen-
trations, 16.4.1 may decrease transactivation function of
Rev, for example by sequestering Rev in inactive com-
plexes in nucleoli. Inactivation of Rev by 16.4.1 could
play a role in protecting the cells from Rev-mediated cyto-
toxicity [62].
Conclusion
HIV-1 infection of human cells involves various interac-
tions between cellular and viral factors (reviewed in [63]).
Some cell types (e.g. astrocytes) can control HIV-1 replica-
tion demonstrating the impact of cellular factors on HIV
infection [60,64]. Identification of cellular factors that are
able to interfere with viral replication will contribute to
understanding of cellular defence mechanisms against
viral intruders and may also lead to identification of new
targets for therapeutic approaches for virus restriction.
Using HIV-1 Rev as "bait" we were able to identify a
previously undescribed cellular interaction partner of an
HIV-1 protein, 16.4.1. The 16.4.1 protein is exported from
the nucleus by CRM1 and accumulates in the cytoplasm.
An important feature of 16.4.1 is its ability to impair
transactivation capacity of Rev, although both proteins
localize to different cellular compartments. Conversely,
Rev is capable of affecting localization of the 16.4.1 pro-
tein by recruiting it to the nuclei/nucleoli of eukaryotic
cells. Because of its properties we suggest naming the
16.4.1 protein "Risp" (Rev interacting shuttling protein).
Data base analyses and preliminary studies with a specific
monoclonal antibody suggest that human proteins with
Risp sequences are expressed in various human cell types
including HIV-1 target cells. The objective of future stud-
ies will be to characterize Risp proteins, their cellular func-
tions and their influence on Rev activity and HIV-1
replication in different HIV-1 target cells.
This study represents a further step toward elucidating the
network of host cell factors that interact with the HIV-1
Rev protein and influence its functions. This study also
illustrates the power of viral proteins as tools for identifi-
cation and biological characterization of novel cellular
factors. Use of similar experimental strategies as presented
here will help to gain deeper understanding of virus-cell
interactions.
Methods
Plasmids
The inserts of all plasmid constructs used in this study
were verified by sequence analysis (Sequiserve, Germany).
Expression plasmids for yeast two-hybrid analysis
pEG202 [65] was used to express bait proteins containing
various Rev sequences fused to the LexA DNA bindingBMC Cell Biology 2005, 6:20 http://www.biomedcentral.com/1471-2121/6/20
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domain in yeast. pEG202 also expresses the yeast selec-
tion marker His3.
For construction of pEG202-sRev, pBsRev [64,66] was
used as template for PCR amplification to generate the rev
sequence of HIV-1 isolate HXB2; the PCR product was
inserted into the EcoRI site of pEG202. The same proce-
dure was used for construction of bait plasmids pEG202-
RevM4, pEG202-RevM10BL, pEG202-RevM5, pEG202-
RevSLT40, using pcTat-RevM4 [46], pCsRevM10BLsg143
[60], pcRevM5 [45] and pcRevSLT40 [46] as PCR
templates. Bait plasmids used as controls for unspecific
interaction contained the wildtype rev sequence in anti-
sense orientation (pEG202-sRev(antisense)) or encode a
bait protein unrelated to Rev (pEG202-LexCD2).
pJG4-5 and its derivative pJG4-6 was used for galactose-
inducible expression of prey proteins containing the pro-
tein of interest fused to the NLS of SV40 T antigen, and the
B42 transcriptional activator [65]. pJG4-5/6 also express
the yeast selection marker Trp1.
pSH18-34 reporter plasmid contains 8 LexA operators
that direct expression of the lacZ reporter gene.
The expression library used for two-hybrid screening con-
tained cDNAs from human Jurkat T-cells inserted into the
EcoRI/XhoI sites of pJG4-5 [67].
For mapping of Rev-interacting regions of 16.4.1,
sequences encoding full-length 16.4.1 or various frag-
ments of 16.4.1 were generated by PCR amplification
using pC16.4.1sg143 as template and primers adding a 5'
MluI site and a 3' NotI site. PCR products were inserted
into pJG4-6 cleaved with MluI and NotI.
Plasmids pJG4-5, pJG4-6, pEG202, pSH18-34 and the Jur-
kat T-cell cDNA expression library were kindly provided
by Waldemar Kolanus, University of Bonn, Germany.
Expression plasmids for mammalian two-hybrid analysis
Protein interactions in human cells were analysed with
the CheckMate™ Mammalian Two-Hybrid System
(Promega, Madison, USA), which uses pACT and pBIND
vectors and the G5luc reporter plasmid. pACT and pBIND
direct expression of fusion proteins containing the tran-
scriptional activation domain of Herpes virus simplex VP-
16 (pACT) or the Gal4 DNA binding domain (pBIND) at
the N-terminus and potential interactor domains at the C-
terminus. pG5luc contains 5 Gal4-binding motifs and a
minimal promoter for inducible expression of the firefly
luciferase reporter gene.
pACT and pBIND expression plasmids were constructed
by PCR amplification of coding sequences from plasmid
templates with primers adding restriction sites for inser-
tion into the multiple cloning regions of the target vectors.
The rev sequence was generated from pEG202-sRev and
inserted into the SalI site of pACT (pACT-Rev). 16.4.1
sequence was generated from clone DKFZp434O171Q
(RZPD, Berlin, Germany;[68]) and inserted into the
BamHI sites of pACT and pBIND (pACT-16.4.1 and
pBIND-16.4.1). The human CRM1 sequence was ampli-
fied from pChCRM1sg143 [49] and inserted into the
BamHI site of pACT (pACT-hCRM1).
Plasmids encoding GFP-tagged proteins
The vector pFRED143 contains a humanized version of a
strong fluorescent GFP mutant (sg143) under the control
of the CMV immediate early promoter [69]. pC-sg143
plasmids were constructed by using the cloning strategy
described in [60], involving insertion of protein coding
sequences without translational start and stop codons in
frame with gfp-sequences into pFRED at a unique NheI
site located immediately downstream of codon 1 of the
GFP ORF.
The 16.4.1 sequence in pJG4-5 contains a 163 amino acid
reading frame which is terminated by a stop codon but
lacks an initiation codon. A potential translational initia-
tion codon was identified 24 nucleotides upstream of and
in frame with the 16.4.1 sequence in a human fetal cDNA
(Gene Bank Accession Nr. W67699). For construction of
pC16.4.1sg143, the 16.4.1 sequence in pJG4-5 was ampli-
fied with a 5' primer incorporating sequences encoding
amino acids 2–7 into the PCR product, which was
inserted into the NheI site of pFRED143. Sequence analy-
sis of pC16.4.1sg143 verified formation of a single open
reading frame by 16.4.1 and GFP sequences, resulting in
expression of a protein with a predicted molecular mass of
approximately 46 kDa.
For construction of pC16.4.1(74–133)sg143 the sequence
encoding amino acids 74 to 133 was generated by PCR
from pC16.4.1sg143 and inserted into the NheI site of
pFRED143. pC16.4.1(74–133)2sg143 contains tandem
sequences encoding amino acids 74 to 133 of 16.4.1.
The plasmid pC16.4.1(NESmut)sg143 expresses a mutant
16.4.1-GFP fusion protein in which L92, I97 and I99 within
the core nuclear export of 16.4.1 are replaced by alanine
residues. pC16.41(NESmut)sg143 was constructed by
PCR based site directed mutagenesis from pC16.4.1sg143.
For construction of pCRev(52–116)sg143, sequences
encoding amino acids 52–116 of Rev were amplified from
pCsRevsg143 [60] and inserted into the BspEI site of the
pFRED143 variant pFRED143BspEI.BMC Cell Biology 2005, 6:20 http://www.biomedcentral.com/1471-2121/6/20
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pCPKIα  sg143 directs expression of GFP-tagged human
PKI and was constructed as described in [49].
Plasmids encoding IgG1-tagged proteins
pIg was kindly provided by Waldemar Kolanus and was
used for construction of plasmids directing expression of
16.4.1 fusion proteins with an N-terminal IgG1 tag. pIg
contains CH2 and CH3 domain segments from human
IgG1 cDNA in the mammalian expression vector pRK5
[67,70]. Sequences encoding 16.4.1 or various regions of
16.4.1 were amplified from pC16.4.1sg143. PCR products
were inserted into the MluI/NotI sites of the pIg
polylinker, resulting in construction of the following plas-
mids: pIgG1-16.4.1, pIgG1-16.4.1(2–38), pIgG1-
16.4.1(2–133), pIgG1-16.4.1(38–171), pIgG1-
16.4.1(74–171) and pIgG1-16.4.1(134–171).
Plasmids used in Rev activity assay
pLRed(INS)2R reporter plasmid was constructed in a sim-
ilar manner as described for pLRed(p17/p24INS)R [3].
Briefly, a DNA fragment with HIV-1 gag-sequences con-
taining INS 1 and 2 (nucleotides 379–1424 of the HXB2
genome) was isolated from pB37R [71] by ClaI-digestion
and inserted into ClaI-digested and dephosphorylated
pLRedR [3]. pLRed(p17/p24INS)R contains two copies of
the HIV-1 gag sequences in sense orientation. This plasmid
directs Rev and Tat-dependent expression of red fluores-
cent protein (RFP).
pL3Tat contains the HIV-1 tat gene under the control of
the HIV-1 LTR [64].
pCsRev-CFP was established by replacement of the GFP
encoding sequence of pCsRevsg143 mentioned above
with the coding sequence for cyan fluorescent protein
(CFP).
Yeast two-hybrid assay
The yeast interaction trap was performed essentially as
described in [65,67], using yeast strain EGY48 which con-
tains the LEU2 gene under the control of LexA operators
and has defective leu2,  his3,  trp1  and  ura3  genes. The
pEG202-sRev bait plasmid was transformed into yeast
strain EGY48 bearing the pSH18-34 reporter plasmid.
This "bait" strain was transformed with the Jurkat T-cell
library contained in the yeast expression plasmid pJG4-5.
Criteria for protein-protein interactions were growth on
medium containing galactose and lacking uracil, histi-
dine, tryptophane and leucine, no growth in the same
medium containing glucose instead of galactose, and
expression of beta-galactosidase. Forty-six yeast trans-
formants were obtained that grew on selective medium
and expressed the lacZ reporter gene. cDNAs from those
yeast clones were purified by passaging through E. coli
KC8 and retested for interaction with pEG202-sRev but
not with control bait plasmids pEG202-sRev(antisense)
and pEG202-LexCD2 to confirm specific interaction.
Mammalian two-hybrid assay
Mammalian two-hybrid assay was performed in HEK293
cells, using the CheckMate™ Mammalian Two-Hybrid Sys-
tem (Promega, Madison, USA).
HEK293 cells were cotransfected with pBIND and pACT
constructs for expression of VP16 and Gal4 proteins fused
to potential interactor domains (1 µg each) and with the
pG5luc reporter plasmid (2 µg). For each interactor assay,
parallel transfections were performed with G5luc and
pBIND and pACT vectors expressing Vp16 and Gal4 with-
out interactor domains to determine background expres-
sion of the luciferase gene. Two days after transfection
cells were lysed, and firefly luciferase activity (in relative
light units per second, RLU/s) quantified using the Luci-
ferase Reporter Assay System (PROMEGA) and the
ORION I Microplate Luminometer (Berthold Detection
Systems, Pforzheim, Germany). The total amount of pro-
tein in cell lysates was quantified using the BCA Protein
Assay Reagent Kit (Pierce Chemical Co., Rockford, USA)
and luciferase activity (RLU/s) standardized to 1mg of
total protein in the cell lysate. Values are expressed as fold-
induction of luciferase activity over basal expression
levels.
Cell culture, transfection and Leptomycin B treatment
HeLa and HEK293 cells were maintained in Dulbecco's
Modified Eagle Medium containing 2 nM Glutamax I
(Life Technologies, Karlsruhe, Germany) and 10% fetal
calf serum (Seromed, Berlin, Germany).
All transfection experiments were performed in 35-mm-
diameter dishes (BD Biosciences, Bedford, MA, USA).
Cells were seeded at a density of 1 × 105 cells per dish one
day prior to transfection and cultured for 24 h after trans-
fection. HEK293 cells were transfected by calcium phos-
phate coprecipitation using the CellPhect kit (Pharmacia,
Freiburg, Germany). Transfection of HeLa cells was per-
formed with the FuGENE™6 Transfection Reagent (Roche
Diagnostics, Mannheim, Germany) using 500 ng plasmid
DNA per dish.
Leptomycin B (LMB, Sigma-Aldrich, Munich, Germany)
treatments were performed 24 hours after transfection at
a concentration of 5 nM LMB for 2 hours. For microinjec-
tion experiments, LMB was added at a concentration of 10
nM 2 hours prior to injection.
For evaluation and quantification of fluorescence, cells
were fixed with 4% paraformaldehyde (PFA) for 30 min-
utes at room temperature; nuclei were stained withBMC Cell Biology 2005, 6:20 http://www.biomedcentral.com/1471-2121/6/20
Page 19 of 22
(page number not for citation purposes)
Hoechst 33343 (Molecular Probes Europe BV, Leiden,
Netherlands) for 10 minutes.
Toxic influences of long-term expression of 16.4.1-GFP in
HeLa cells were assessed by CytoTox-ONE™ and CellTiter-
Glo™ cell viability assays (Promega, Madison, USA)
according to manufacturer's instructions.
The cell line HeLa 16.4.1-GFP expresses 16.4.1-GFP con-
stitutively and was established by transfection with
pC16.4.1sg143 followed by G418-selection (80 µg/ml).
Non-fluorescent antibiotic resistant cells were excluded by
FACS sorting.
Immunological methods
Immunocytochemistry
Cells were fixed with PFA (4%) and permeabilized with
TritonX-100 (0.2%).
IgG1-16.4.1 fusion proteins were detected by direct stain-
ing with a Cy3-conjugated goat anti-human IgG1 anti-
bodies (Dianova, Hamburg, Germany), diluted 1:200 in
phosphate buffered saline containing 1% BSA. For detec-
tion of 16.4.1 antigens, a monoclonal antibody against
16.4.1 (Kramer-Hämmerle et al. in preparation) was used
as primary antibody and a Cy3-conjugated goat anti-rat
antibody (Dianova, Hamburg, Germany) as secondary
antibody.
Western Blot
Whole cell lysates were prepared with RIPA buffer con-
taining protease inhibitors (protease inhibitor cocktail;
Sigma, Taufkirchen, Germany) and separated on either
precast 4–12% Bis-Tris or 3–8% Tris-Acetate gradient gels
(Invitrogen, Karlsruhe, Germany). After transfer onto
nitrocellulose membranes, proteins were probed with pri-
mary polyclonal rabbit antibodies against GFP (Chemi-
con Europe, Hofheim, Germany) or with the 16.4.1-
specific monoclonal antibody and with HRP-conjugated
secondary goat anti-rabbit or anti-rat antibodies (Dian-
ova, Hamburg, Germany). Protein bands were detected by
an enhanced chemiluminescence system (Perbio Science,
Bonn, Germany).
Quantitative fluorescence microscopy
Microscopy of cells expressing fluorescent proteins and
quantitative analysis of subcellular distribution of fluores-
cence was performed as described [49]. Images for quan-
tification were taken at 32-fold magnification with
flexible exposure times and evaluated by IPlab software
for fluorescence values below pixel saturation. Each cell
group was photographed as phase contrast and fluores-
cence images for Hoechst 33342 and GFP.
3D deconvolution and widefield multichannel unmixing 
microscopy
Fluorescence microscopic imaging, 3D deconvolution
and widefield multichannel unmixing was carried out
with a computer-controlled Zeiss Axiovert 200 M research
microscope ("Cell Observer") with scanning stage (Carl
Zeiss, Goettingen, Germany) and Software AxioVision 4.2
(Carl Zeiss Vision, Hallbergmoos, Germany). Images of
2% PFA-fixed specimen were acquired using a Zeiss 40×/
1.3 Plan Neofluar objective and Zeiss filter sets No. 44
(GFP), 49 (Hoechst33342) and 47 (CFP). Z-stacks with
100 optical sections at 0.325 µm intervals were captured
with a Zeiss AxioCam HRm CCD-Camera with full resolu-
tion of 1388 × 1044 pixels. Deconvolution of fluorescence
images [72] was carried out with AxioVision 4.2 software
using a constrained iterative algorithm and auto linear
normalization. Subsequently widefield multichannel
unmixing was performed on the deconvolved image-
stacks to correct for fluorescence bleedthrough of
Hoechst-, CFP- and GFP- signals. Three reference samples
with either one of the three fluorochromes were prepared,
reference measurements were performed and a 3 × 3
matrix was generated that was used to unmix the sample
image-stack. Processed images were then arranged for
presentation and exported with AxioVision 4.2 software.
Microinjection experiments
Compounds for microinjection were generated and
microinjections were performed as described previously
[49,51]. Briefly, bovine serum albumin (BSA) was first
labeled with Alexa-red (excitation 568 nm, Molecular
probes) and subsequently conjugated to the following
peptides:
(1.) HIV-1 Rev-NES represented by -CGG-LQPPLERLTLD
and (2.) 16.4.1 amino acids 86 to 105 -CG-KTLESNLFDD-
NIDIFADLTV. Both peptides were synthesized by Sigma-
Genosys. For coinjections unconjugated BSA labeled with
Alexa-green (excitation 488 nm, Molecular probes) was
used. Peptide solutions with a concentration of 1 mg/ml
were injected into the nuclear compartment of HeLa cells.
Two hours after injection, cells were fixed with 4% PFA,
images of green and red channels were taken and the per-
centages of red (BSA-conjugated peptides) and green
(unconjugated BSA) fluorescent signals were determined.
The ratio between red and green fluorescence in the
nuclear and cytoplasmic compartments indicates the rela-
tive translocation activity of the peptide.
Rev activity assay
The Rev activity assay was performed essentially as
described previously [3]. Transfections were performed in
6-well plates using FUGENE™6 according to the manufac-
turer's protocol with 1 µg pLRed(INS)2R, 0.2 µg pL3Tat,
0.1 µg pCsRev-CFP and 0.1 µg pFRED143. To evaluate theBMC Cell Biology 2005, 6:20 http://www.biomedcentral.com/1471-2121/6/20
Page 20 of 22
(page number not for citation purposes)
influence of 16.4.1-GFP on Rev-activity, pC16.4.1sg143
(0.5 µg or 1 µg) was added to the transfection mixture.
Expression of fluorescent fusion proteins was checked by
microscopy 24 hours after transfection and cells were
analysed by flow cytometry. Typically 100,000 cells of
each transfected well were analysed with a Becton Dickin-
son FACSCalibur flow cytometer equipped with a 488 nm
argon laser and controlled by the software CellQuest Pro.
GFP-fluorescence was analysed in channel FL-1 and RFP-
fluorescence in FL-3. The percentage of reporter positive
cells (RFP) in the transfected cell population (GFP) was
determined.
RNAi interference in combination with Rev activity assay
For down-regulation of gene expression, 16.4.1 specific
(siRNA-16.4.1) and non-specific (siRNA-nsp) and a GFP-
specific siRNA were designed and synthesized by Qiagen.
Transfections were carried out using RNAiFect transfec-
tion reagent (Qiagen) according to supplier's protocol.
Target cells were seeded one day prior to transfection in 6-
well plates, 5 µg siRNA per well were used for each trans-
fection. Silencing effects of GFP-fusion proteins were
determined by FACS analyses 48 hours after transfection.
For the combined RNAi-Rev activity experiments, siRNA
transfection was performed 24 h prior to DNA
transfection.
Bioinformatics
In silico identification and analysis of sequences were per-
formed using the databases and bioinformatics tools of
NCBI [73] and of Genomatix Software GmbH [74].
Similarities between nuclear export signals in the NES
database NESbase 1.0 [75] were analysed with a set of
amino acid weight matrices adapted from the MatInspec-
tor algorithm [76] using the BLOSSOM similarity matrix
values to account for conserved amino acid substitutions.
Reading frames were predicted with the tool ATGpr [77].
Statistics
Statistical analysis of data was carried out with the Graph-
PadPRISM program (GraphPad Software Inc., San Diego,
CA, USA). Significances of differences between data sets
were determined by calculating two-tailed P values by the
Mann-Whitney U test.
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Additional material
Additional File 1
Schematic representation of cDNAs with 16.4.1-coding sequences in pre-
dicted open reading frames. The scheme shows various cDNAs with 
16.4.1 sequences identified by BLAST search of Entrez databases ([73] 
(indicated by lines). Open reading frames (ORF) were predicted with the 
ATGpr program [77]. Bars indicate the locations of the predicted ORFs 
within the cDNAs. The positions of the potential translation initiation and 
stop codons are marked by M and *, respectively. Regions with 16.4.1 
encoding sequences are labeled yellow. All accession numbers are from the 
GenBank database.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2121-6-20-S1.pdf]
Additional File 2
Sizes of hypothetical 16.4.1 cDNAs and proteins. The table indicates the 
lengths of the cDNAs shown in Additional file 1: Figure A1 and the cal-
culated sizes of the proteins they are predicted to encode.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2121-6-20-S2.pdf]
Additional File 3
Analysis of expression of 16.4.1 proteins with a monoclonal antibody 
directed against 16.4.1. Figure A2 shows expression of 16.4.1 proteins in 
HeLa cells. (A) Immunohistochemical analysis. Expression of 16.4.1 was 
detected in HeLa cells transfected with pIgG-16.4.1 (panel a) and in non-
transfected HeLa cells (panel b) by indirect immunofluorescence with the 
monoclonal antibody against 1.6.4.1 and Cy3-labelled secondary anti-
bodies. Panel c shows lack of reactivity of non-transfected HeLa cells with 
the secondary antibody. All images were taken with the same exposure 
times (300 ms). (B) Western blot analyses. Additional to 16.4.1-GFP 
several proteins are detected in HeLa cells expressing 16.4.1-GFP after 
transfection of pC16.4.1sg143. Proteins in whole-cell lysates were sepa-
rated by electrophoresis in gradient gels (4–12% and 3–8%), and blotted 
onto nitrocellulose membranes. 16.4.1 proteins were detected with the 
monoclonal 16.4.1 antibody and a secondary antibody conjugated with 
horse radish peroxidase (HRP). For detection of the 16.4.1-GFP fusion 
protein, the membranes were stripped and reprobed with polyclonal anti-
bodies against GFP. Table A2 lists proteins recognized by the monoclonal 
antibody against 16.4.1 in different human cell lines and primary human 
tissues by Western blot analyses. HeLa (cervix carcinoma) and 293T 
(embryonal kidney) cell lines are non-neural cells and U138MG, 
U251MG and 85HG66 human glioblastoma cell lines. Human cortical 
brain tissue and peripheral blood mononuclear cells were also investigated.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
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